

Reference Number: FOI202223/670
From: Private Individual
Date: 31 March 2023
Subject: Usage of Dabrafenib + Trametinib in cancer treatment

Q1 I would be grateful if you could please answer these questions relating to the usage of Dabrafenib + Trametinib in cancer treatment.

Over the previous 6 months, how many patients for the following diseases have been treated with a combination of Dabrafenib + Trametinib:

- i) Metastatic Melanoma
- ii) Adjuvant Melanoma
- iii) BRAF mutated Lung Cancer

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.